CSL Limited is buying Vifor Pharma for $11.7 billion, a deal that gives it access to Vifor’s iron deficiency, kidney and cardio-renal disease treatments. CSL aims to expand beyond its blood plasma collection business, which declined during the pandemic. (Reuters)

Bristol Myers Squibb is putting down $150 million in cash and $770 million in milestones for a partnership with Immatics, maker of the bispecific IMA401. IMA401 is part of an “emerging modality for solid tumors with the potential for cell therapy-like efficacy,” BMS’ Teri Foy said. (Endpoints News)

Retail pharmacists are complaining of burnout due to an increased push for COVID-19 vaccines and medications, as well as staff shortages. Walgreens, CVS and Rite Aid are hiring more employees to meet the higher demand. (Business Insider)

Amid ongoing COVID-19 outbreaks, the NFL is mandating booster shots and the NBA has postponed several games. While 97% of NBA players are vaccinated, protocols mandate that players must test negative for COVID-19 within 24 hours before returning to play. (CNBC Weekly)

Many patients are seeking physicians of their own race or ethnicity in hopes of removing bias and receiving better care. “Doctors who come from marginalized roots offer the particular value of being someone who knows they are not the center of attention,” Ryan Huerto told The Washington Post. (The Washington Post)